Aspire Biopharma Holdings, Inc., was formed on February 9, 2021, and is a Delaware corporation. The company is an early-stage biopharmaceutical company in the business of developing and marketing disruptive technologies for new delivery mechanisms, initially for "no harm" drugs. To date, Aspire has developed and acquired disruptive technologies, which are new soluble formulations designed to address issues such as emergencies, drug efficacy, dose management and response time. Aspire's focus is to develop any number of soluble, PH-neutral, quick-acting powder or granular forms that allow rapid sublingual absorption of the product. 

ASBP

ASBP Profile